IFRS 15 Revenue for the Pharmaceutical sector | KPMG | GR
close
Share with your friends

IFRS 15 Revenue for the Pharmaceutical sector

IFRS 15 Revenue for the Pharmaceutical sector

IFRS 15 will change the way many pharma companies account for sales contracts.

1000

Partner, Deal Advisory and Forensics, Head of Accounting Advisory Services

KPMG in Greece

Contact

Related content

IFRS 15 Pharma

IFRS 15 will change the way many pharma companies account for sales contracts. To help you drive your implementation project to the finish line, we’ve pulled together a list of key considerations that many pharma companies need to focus on.

© 2018 KPMG Advisors AE, a Greece Corporation and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved.

KPMG International Cooperative (“KPMG International”) is a Swiss entity.  Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm.

Connect with us

 

Request for proposal

 

Submit